Apogee Therapeutics, Inc. Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE

Classificação em ações #2352
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Preço da ação
$135.07
Última sincronização: 2026-09-04
Valor de mercado
$8.36B
Variação (1 dia)
0.00%
Variação (1 ano)
137.21%
País
US
Negociar Apogee Therapeutics, Inc. (APGE)

Categoria

Healthcare
Histórico de rendimento de dividendos para Apogee Therapeutics, Inc. (APGE)
O rendimento de dividendos (TTM) da Apogee Therapeutics, Inc. (símbolo da ação: APGE) em 2023-12-31 é: 0.00%
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para Apogee Therapeutics, Inc. (APGE) de 2022 a 2026
Rendimento de dividendos no final de cada ano (TTM)
Ano Rendimento de Dividendos Alterar
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes
Empresa Rendimento de Dividendos País
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL